B

Braidwell Portfolio holdings

AUM $2.7B Turnover 43.12%
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+5.48%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.53B
AUM Growth
+$340M
Cap. Flow
-$901M
Cap. Flow %
-25.54%
Top 10 Hldgs %
34.64%
Holding
89
New
15
Increased
24
Reduced
22
Closed
8
Avg Time Held
0.8 years
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
0.7 years

Top Buys

Rank Stock Value
1
APLS icon
Apellis Pharmaceuticals
APLS
+$93.1M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$47M
3
BCAX icon
Bicara Therapeutics
BCAX
+$42.3M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$39.9M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$39M

Top Sells

Rank Stock Value
1
EXAS icon
Exact Sciences
EXAS
+$48.3M
2
PCVX icon
Vaxcyte
PCVX
+$46M
3
TMO icon
Thermo Fisher Scientific
TMO
+$39M
4
APGE icon
Apogee Therapeutics
APGE
+$35.9M
5
ARGX icon
argenx
ARGX
+$35.5M

Sector Composition

Rank Sector Weight
1 Healthcare 65.68%
2 Miscellaneous 34.16%
3 Consumer Staples 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CGON icon
1
CG Oncology
CGON
$5.48B
$120M 3.39%
3,170,875
-138,632
-4% -$4.86M
2024 Q1
2 quarters
XENE icon
2
Xenon Pharmaceuticals
XENE
$3.28B
$107M 3.02%
2,707,255
+146,682
+6% +$5.91M
2022 Q4
7 quarters
NBIX icon
3
Neurocrine Biosciences
NBIX
$13.8B
$106M 3%
917,674
+158,665
+21% +$21.8M
2023 Q1
6 quarters
APGE icon
4
DELISTED
Apogee Therapeutics
APGE
$96.5M 2.74%
1,643,226
-748,816
-31% -$35.9M
2023 Q3
4 quarters
APLS icon
5
DELISTED
Apellis Pharmaceuticals
APLS
$90.1M 2.55%
3,125,183
+2,513,383
+411% +$93.1M
2024 Q2
1 quarter
ALGN icon
6
Align Technology
ALGN
$10.3B
$79.3M 2.25%
311,679
+36,472
+13% +$8.61M
2022 Q4
7 quarters
GH icon
7
Guardant Health
GH
$21.9B
$76.7M 2.17%
3,342,124
+534,156
+19% +$15.1M
2023 Q2
5 quarters
LEGN icon
8
Legend Biotech
LEGN
$3.7B
$75.1M 2.13%
1,541,551
-128,169
-8% -$6.83M
2022 Q4
7 quarters
VKTX icon
9
Viking Therapeutics
VKTX
$3.24B
$73.2M 2.08%
1,156,977
+50,072
+5% +$2.94M
2024 Q1
2 quarters
KNSA icon
10
Kiniksa Pharmaceuticals
KNSA
$6.15B
$72.3M 2.05%
2,894,513
+836,210
+41% +$20.4M
2024 Q1
2 quarters
PEN icon
11
Penumbra
PEN
$12.6B
$70.2M 1.99%
361,428
+148,834
+70% +$28.1M
2022 Q4
7 quarters
MRVI icon
12
Maravai LifeSciences
MRVI
$976M
$69.4M 1.97%
8,353,287
-670,750
-7% -$5.8M
2023 Q2
5 quarters
DAWN icon
13
DELISTED
Day One Biopharmaceuticals
DAWN
$67.9M 1.92%
4,873,853
+1,837,949
+61% +$26.2M
2022 Q4
7 quarters
SYRE icon
14
Spyre Therapeutics
SYRE
$7.35B
$64.4M 1.83%
2,189,836
-324,702
-13% -$9.04M
2023 Q4
3 quarters
RGEN icon
15
Repligen
RGEN
$11.3B
$59M 1.67%
396,781
+73,272
+23% +$10.5M
2023 Q2
5 quarters
IRTC icon
16
iRhythm Holdings
IRTC
$3.5B
$58.1M 1.65%
782,557
+256,200
+49% +$20.4M
2022 Q4
7 quarters
ARGX icon
17
argenx
ARGX
$51.5B
$52.4M 1.49%
96,724
-70,200
-42% -$35.5M
2023 Q4
3 quarters
EWTX icon
18
Edgewise Therapeutics
EWTX
$4.02B
$52.3M 1.48%
+1,958,310
New +$39M
2024 Q3
0 quarters
INSP icon
19
Inspire Medical Systems
INSP
$1.97B
$50.4M 1.43%
238,911
-140,532
-37% -$24.4M
2023 Q3
4 quarters
SRPT icon
20
Sarepta Therapeutics
SRPT
$1.78B
$46.3M 1.31%
370,400
+288,500
+352% +$39.9M
2024 Q2
1 quarter
ISRG icon
21
Intuitive Surgical
ISRG
$148B
$44.9M 1.27%
91,300
-9,200
-9% -$4.28M
2024 Q1
2 quarters
AVDL
22
DELISTED
Avadel Pharmaceuticals
AVDL
$44.4M 1.26%
3,388,939
+490,300
+17% +$7.47M
2024 Q1
2 quarters
BCAX icon
23
Bicara Therapeutics
BCAX
$1.15B
$42.2M 1.2%
+1,657,600
New +$42.3M
2024 Q3
0 quarters
KROS icon
24
Keros Therapeutics
KROS
$219M
$41.1M 1.16%
707,240
-274,969
-28% -$13.6M
2023 Q2
5 quarters
GKOS icon
25
Glaukos
GKOS
$9.9B
$40.6M 1.15%
311,616
-184,960
-37% -$23M
2022 Q4
7 quarters
1
2 3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q3 2024 Portfolio in Review

As of Q3 2024, Braidwell held 89 positions worth $3.53B, up 11% from $3.19B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Braidwell withdrew a net $901M in Q3 2024, closing 8 positions and reducing 22 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 61% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Madrigal Pharmaceuticals worth $39M.

  • Braidwell's largest Q3 2024 buy was Madrigal Pharmaceuticals: 183,818 shares worth $39M.
  • Braidwell added most to Apellis Pharmaceuticals in Q3 2024, an estimated $93.1M increase.
  • Braidwell's biggest Q3 2024 reduction was Exact Sciences, cutting an estimated $48.3M.
  • Braidwell fully exited Thermo Fisher Scientific in Q3 2024, selling an estimated $39M.
  • Braidwell's ten largest holdings make up 35% of its $3.53B portfolio in Q3 2024.
  • Braidwell opened 15 new positions and closed 8 in Q3 2024.
  • Braidwell's portfolio value rose 11% quarter-over-quarter to $3.53B.

Based on Braidwell's 13F filing for Q3 2024, filed 14 Nov 2024.